But it's important to get any symptoms checked out by your GP. Cancer can also spread to your bones from somewhere else. This is called secondary or metastatic bone cancer. The signs and symptoms of ...

A new dyslipidemia guideline from the American Association of Clinical Endocrinology (AACE) offers evidence-based recommendations for the use of newer drugs and focuses on outcomes that are ...

Dr MKO AbimbolaDiabetes is a long-term condition caused by defi­ciency in quantity or function of insulin, the chemical controlling the level of sugar in the blood. People with diabetes par­ticularly ...

Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

In addition, the management of dyslipidemia in patients with diabetes and metobolic syndrome is addressed, and the differences between the old and new guidelines are highlighted. The ATP III ...

However, if left untreated, it can cause a weakened immune system or acquired immune deficiency syndrome (AIDS). Some people may not develop any symptoms after contracting HIV and could remain ...

Vagaggini helps us to understand that each of the liturgical signs of the sacraments has four dimensions, which bring together the past, present and future. The four dimensions of the sacraments ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

At baseline, 78.4% of patients had an LVEF ≤45%, and 57.0% had signs or symptoms of congestion that resulted in treatment during the index hospitalization. Results showed that first hospitalization ...

A family-owned restaurant offering locally sourced and made-from-scratch breakfast and lunch, the Joyful Cafe opened this week at the Running Y Ranch to positive reviews.

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...